Seeking Alpha
 

Nymox Pharmaceutical Corporation (NYMX)

- NASDAQ
  • Fri, Feb. 27, 1:40 PM
    • Thinly-traded nano cap Nymox Pharmaceutical (NYMX +27%) jumps on a more than a 7x surge in volume on no news.
    • Shares collapsed in early November after the company reported the failure of two clinical trials assessing NX-1207 in benign prostate hyperplasia.
    • Previously: Nymox plummets after failure of BPH trials (Nov. 3, 2014)
    | Comment!
  • Nov. 3, 2014, 12:49 PM
    | 1 Comment
  • Nov. 3, 2014, 9:29 AM
    | Comment!
  • Nov. 3, 2014, 9:13 AM
    | Comment!
  • Oct. 6, 2014, 12:46 PM
    | Comment!
  • Sep. 9, 2013, 12:46 PM
    | Comment!
  • Aug. 22, 2013, 3:24 PM
    • Nymox Pharmaceuticals (NYMX +3.1%) says the Safety Monitoring Committee's most recent review of safety data for NX-1207, its drug candidate to treat benign prostatic hyperplasia, found no significant safety concerns to date.
    • NX-1207 is currently is in Phase III development in the U.S. and in the E.U. by licensing partner Recordati SpA.
    • The drug has so far shown none of the adverse sexual side effects associated with previously approved medical and surgical treatments for BPH.
    • Both Phase III trials have completed enrollment and treatment and patient evaluation is continuing at over 70 urology investigative sites across the U.S.
    | Comment!
  • Jul. 16, 2013, 3:45 PM
    Nymox Pharmaceutical (NYMX +6.4%) pops on an upbeat article out of Seeking Alpha, saying the company may be the next unknown biotech to ramp higher. The blog points out the company is in the early stages of marketing AlzheimAlert, NicAlert and TobacAlert, which are diagnostic tests for diagnosing Alheimer's disease and measuring tobacco exposure, all of which may have significant upside potential. Trials are set to close late this year, and the window to invest while it's relatively unknown is closing.
    | Comment!
  • Jul. 16, 2013, 12:41 PM
    Midday top 10 gainers: SHFL +22%. SOL +20%. ESMC +19%. NYMX +15%. NTLS +15%. DRAM +14%. FST +12%. STP +11%. EPZM +11%. LDK +9%.
    Midday top 10 Losers: JOEZ -22%. BBGI -19%. HSII -16%. KOOL -16%. ADUS -14%. HGSH -12%. STMP -11%. XONE -10%. LQDT -9%. ENG -9%.
    | Comment!
  • May. 15, 2013, 12:54 PM
    Nymox Pharmaceutical (NYMX +3%) gains on an upbeat Q1 report, halving its losses and more than doubling revenue Y/Y. The drug-maker posted a $0.03 per share net loss, down from a $0.06 per share loss during the same quarter last year and beating analyst forecasts for a loss of $0.05. Revenue surged 116% to $184K, which also easily topped expectations by over $105K, largely due to licensing agreements and an increase in orders from one customer for NicAlert/TobacAlert.
    | Comment!
  • May. 3, 2013, 1:56 PM
    Nymox Pharmaceutical (NYMX +5%) jumps after completing enrollment in a final, pivotal Phase III trial for its benign prostatic hyperplasia treatment NX-1207. Previous results suggest the drug may be able to double average symptomatic improvements compared to conventional treatments. (I, II, III)
    | Comment!
  • Apr. 16, 2013, 3:41 PM
    Nymox Pharmaceutical (NYMX -0.8%) gives back gains made earlier in the day as the market shrugs off its announcement of positive data on NX-1207, its treatment for benign prostatic hyperplasia. The company says the drug has no detectable effect on sexual function in test subjects. Other drugs that are currently used to treat prostate ailments frequently cause collateral damage to sexual organs.
    | 1 Comment
  • Mar. 18, 2013, 4:03 PM
    Shares of Nymox Pharmaceutical (NYMX +25.2%) soar today, going out at their highs as the company says it will present data on NX-1207 at the European Association of Urology's annual meeting held in Milan, Italy. NX-1207 is in late stage Phase 3 development in the U.S. for the treatment of BPH, a common condition of older men associated with growth in prostate size as men age.
    | 1 Comment
  • Mar. 18, 2013, 12:48 PM
    Midday top 10 gainers: YRCW +25%. PRWT +22%. ULTR +17%. IG +17%. CHYR +16%. ATOS +14%. TA +13%. NYMX +13%. WILC +11%. SORL +11%.
    Midday top 10 losers: AMBO -19%. PTX -12%. SOL -10%. CNET -10%. EMITF -9%. TSEM -8%. MNDO -8%. RGDX -8%. JVA -8%. AMBA -8%.
    | 1 Comment
  • Mar. 5, 2013, 4:01 PM
    Nymox Pharmaceutical (NYMX +3.2%) is set to close in the green today after the company provided a positive update on Phase 2 clinical trials for NX-1207, a drug being tested for early-stage prostate cancer. The trial has reached the halfway point in patient recruitment and safety assessments to date have shown no serious or unexpected adverse effects. The drug is also in Phase 3 clinical trials for treating benign prostatic hyperplasia and has been tested in 10 trials to date, of which 6 are ongoing or nearing completion.
    | Comment!
  • Nov. 28, 2012, 11:37 AM
    Nymox Pharmaceutical (NYMX +3.4%) says it's completed the patient enrollment process for its Phase III trial of NX-1207 for BPH. Top-line results are expected in late 2013, and include pivotal studies in the U.S. and Europe, re-injection studies in the U.S., prostate cancer trials, as well as other clinical and non-clinical research activities.
    | Comment!
Visit Seeking Alpha's
NYMX vs. ETF Alternatives
Company Description
Nymox Pharmaceutical Corp along with its subsidiaries is a biopharmaceutical corporation, engaged in research and development of diagnostics and drugs for brain disorders and diseases of the aged with an emphasis on Alzheimer's disease.
Sector: Healthcare
Country: Canada